Amgen stock (US0311621009): earnings beat and leadership change put biotech giant in focus

Amgen surprised with stronger Q3 2024 earnings and is reshaping its finance leadership. What the latest numbers, guidance and CFO transition could mean for the Nasdaq-listed biotech heavyweight.

Amgen delivered stronger-than-expected earnings for the quarter ended September 2024 and combined this with an ongoing leadership transition in its finance team, keeping the Nasdaq-listed biotech heavyweight firmly on the radar of US investors, according to Zacks as of 11/01/2024 and a governance-focused piece from Simply Wall St as of 04/09/2024.

According to earnings data compiled by Zacks, Amgen reported earnings of 5.58 USD per share for the September 2024 quarter, above the consensus estimate, highlighting continued profitability despite rising competition in key therapy areas, as summarized by Zacks as of 11/01/2024.

As of: 05/24/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology, pharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe and selected global regions
• Key revenue drivers: Innovative biologic therapies and biosimilars
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: US dollar (USD)

Amgen: core business model

Amgen is one of the largest independent biotechnology companies globally, with a focus on discovering, developing and manufacturing innovative human therapeutics. The group historically built its franchise around biologic medicines in areas such as oncology, inflammation and bone health, and it continues to invest heavily in research and development to expand its portfolio, as outlined in its corporate materials published on 02/01/2024 on its website.

The company’s business model combines proprietary biologic drugs with a growing biosimilars platform. Biologics generally command premium pricing due to their complexity, while biosimilars allow Amgen to compete as lower-cost alternatives to off-patent reference biologics. This dual approach is intended to smooth revenue volatility as older products mature and face competition, according to Amgen’s 2023 annual report released on 02/01/2024.

In addition to internal R&D, Amgen uses licensing deals and targeted acquisitions to refresh its pipeline and add late-stage or commercial assets. This business development strategy aims to complement organic innovation and has been visible in recent years through multiple transactions in oncology and rare diseases, according to company transaction overviews updated in 2023 and 2024.

Main revenue and product drivers for Amgen

Amgen’s revenue base is diversified across several blockbuster and near-blockbuster medicines. Historically, products such as Enbrel for inflammatory diseases and Prolia for osteoporosis have been major contributors, while newer therapies in oncology and cardiovascular disease are gradually increasing their share of sales, as described in Amgen’s full-year 2023 results released on 02/06/2024.

The company has also developed a portfolio of biosimilars that target high-value reference products in oncology and immunology. These biosimilars generate revenue while broadening patient access to biologic therapies. This segment has been presented by management as a long-term growth pillar, especially in international markets, based on commentary from Amgen’s 2023 annual report published on 02/01/2024.

Geographically, the United States remains Amgen’s most important market by sales, supported by its Nasdaq listing and deep relationships with American healthcare providers and payers. At the same time, the company is working to expand in Europe and other regions, where biosimilars in particular can gain traction due to cost pressures and tender-driven procurement, according to regional revenue breakdowns in Amgen’s 2023 Form 10-K filed on 02/08/2024.

Recent earnings performance and guidance signals

For the quarter ended September 2024, Amgen reported earnings of 5.58 USD per share, exceeding the Zacks Consensus Estimate and showcasing solid profitability in a challenging pricing environment, according to earnings information compiled by Zacks as of 11/01/2024. Revenue grew versus the prior-year period, driven by newer products and biosimilars, based on Amgen’s earnings release published in late October 2024.

Management used the 2024 earnings cycle to refine full-year guidance, pointing to continued cost discipline and integration of recent acquisitions. While exact guidance figures vary by update, the narrative centers on moderate top-line growth and efforts to sustain operating margins despite inflationary pressures in manufacturing and clinical development, as discussed in Amgen’s Q3 2024 earnings materials released in October 2024.

In 2023, Amgen reported full-year revenue in the mid-20 billion USD range and adjusted earnings per share in the mid-teens, reflecting both growth from newer medicines and headwinds for mature products, according to its full-year 2023 results released on 02/06/2024. Year-on-year trends were influenced by volume growth, competitive dynamics and foreign exchange, as detailed in the same release.

CFO transition and board structure in focus

Beyond the numbers, governance and leadership have become a notable discussion point for Amgen investors. A recent analysis highlighted the company’s chief financial officer transition and broader board structure as potential drivers of strategic change, emphasizing how management composition can influence long-term capital allocation and risk oversight, according to Simply Wall St as of 04/09/2024.

The CFO transition comes at a time when Amgen is managing integration of acquisitions, large-scale R&D commitments and a changing reimbursement landscape in the United States. A new finance leader can shape how aggressively the company pursues deals, share repurchases and debt reduction, particularly given the sizeable balance sheet following past transactions, as noted in governance commentary summarizing board priorities in 2024.

Board composition also remains in the spotlight. Analysts tracking corporate governance have pointed to the mix of industry experience, tenure and independence on Amgen’s board as factors that may affect oversight of strategy, pipeline risk and environmental, social and governance initiatives. These discussions are part of a broader trend in US large-cap healthcare where investors weigh not only clinical data and financial results but also leadership quality, according to governance research pieces published across 2024.

Share price performance and market valuation

Amgen’s market capitalization underlines its status as a biotech heavyweight. The company had a market cap of about 183.12 billion USD as of 05/22/2026, up roughly 25 percent year over year, according to StockAnalysis as of 05/22/2026. Earlier in 2026, on 03/20/2026, its market cap was reported at 187.49 billion USD, marking a near 10 percent increase over the prior year, based on the same source.

The share price has seen meaningful gains over the past year. One data snapshot showed Amgen trading at 379.42 USD, reflecting a strong advance versus levels below 300 USD observed in late 2024, according to pricing and technical commentary on Financhill as of 05/20/2026. Market watchers point to a supportive backdrop of earnings delivery, pipeline progress and broad investor demand for large-cap defensives within healthcare.

On a technical basis, Amgen’s 200-day simple moving average was recently cited around 332.14 USD with the stock trading well above that level, which some technical research interprets as a constructive trend signal, according to Financhill as of 05/20/2026. However, moving averages are only one aspect of technical analysis and do not guarantee future performance.

Industry trends and competitive position

Amgen operates in a biotechnology landscape characterized by high R&D intensity, regulatory scrutiny and intense competition for both innovator and biosimilar products. The sector has seen payers exert growing pressure on drug prices, while regulators balance the need for innovation with affordability, as reflected in recurring policy discussions in the US and Europe throughout 2024 and 2025.

Within this environment, large, diversified biopharma companies like Amgen can benefit from scale advantages in clinical development, manufacturing and global commercialization. At the same time, they face competition from smaller biotech firms with focused pipelines and from generic manufacturers entering the biologics space via biosimilars. The ability to differentiate products with strong clinical data and real-world outcomes is central to maintaining market share, as highlighted in Amgen’s strategic presentations during its 2023 and 2024 investor updates.

The company’s position in oncology, inflammation and bone health is supported by long-standing physician relationships and deep real-world experience with its medicines. However, patent cliffs and new entrants in immunology and oncology require continuous innovation and lifecycle management. This dynamic underlines why pipeline progress and regulatory milestones are closely watched catalysts for the stock, according to sector commentaries from major investment banks published in 2024.

Why Amgen matters for US investors

For US investors, Amgen represents exposure to large-cap biotechnology with a long operating history, meaningful cash generation and a diversified product base. The stock trades on Nasdaq under the ticker AMGN and is included in major US equity indices, which means it can influence benchmark performance and is widely held across mutual funds and exchange-traded funds tracking healthcare, according to index composition data from leading US index providers updated in 2024.

Because Amgen generates a substantial share of its revenue in the United States, its results are closely tied to the US healthcare system, including Medicare reimbursement policies and commercial insurer negotiations. Regulatory or legislative changes affecting drug pricing, reimbursement levels or biosimilar substitution can therefore have a direct impact on the company’s future earnings trajectory, as outlined in the risk factors section of Amgen’s 2023 Form 10-K filed on 02/08/2024.

In addition, Amgen has historically returned capital to shareholders through dividends and share repurchases. The company’s dividend track record and payout policy make the stock relevant not only for growth-oriented biotechnology investors but also for income-focused US portfolios seeking exposure to the healthcare sector, according to dividend history summaries from major financial data providers updated in 2024.

Risks and open questions

Amgen faces a range of risks typical for global biopharma companies. Patent expirations and competitive launches can pressure prices and volumes for key products, while clinical and regulatory setbacks can affect pipeline assets that are expected to drive future growth. These uncertainties are emphasized in Amgen’s detailed risk disclosures in its 2023 Form 10-K filed on 02/08/2024.

Pricing and reimbursement risk in the United States is another central issue. Policy debates around drug costs, including potential reforms aimed at expanding price negotiations or changing rebate structures, could influence revenue and margin expectations. Amgen has acknowledged these headwinds in its 2023 and 2024 earnings materials, stressing cost control and portfolio diversification as partial mitigants.

Finally, integration of acquisitions and successful execution of the company’s strategic plan will be watched closely, especially during leadership transitions in the finance function. Investors will likely scrutinize how the new CFO and the board balance investment in R&D and business development with shareholder returns and balance sheet strength, as highlighted in governance discussions including the analysis from Simply Wall St as of 04/09/2024.

Conclusion

Amgen combines the profile of a mature, cash-generative biotech leader with ongoing exposure to R&D, regulatory and pricing risks. Recent earnings beats, a solid market capitalization above 180 billion USD and an active capital allocation strategy underscore its significance in US healthcare portfolios, while the CFO transition and evolving board oversight introduce an additional layer of strategic uncertainty. For investors following large-cap biotechnology, the interplay between Amgen’s product performance, pipeline milestones, governance developments and US policy dynamics will likely remain a key focus over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.